AstraZeneca faces uphill battle at upcoming adcomm in face of FDA questions

FDA Raises Doubts on AstraZeneca's Cancer Drugs Ahead of Adcomm

The FDA has released briefing documents raising significant doubts about two AstraZeneca cancer drugs, camizestrant and Truqap, ahead of an advisory committee meeting on April 30. For camizestrant, an oral SERD for HR-positive, HER2-negative breast cancer, the agency questioned the clinical meaningfulness of the 56% decrease in risk of death or disease progression and the novel trial design of the Phase 3 SERENA-6 study. For Truqap, an AKT inhibitor proposed for metastatic hormone-sensitive prostate cancer in combination with abiraterone, the FDA acknowledged the 19% improvement in radiographic PFS but noted the overall benefit appeared small and questioned the attribution of benefit due to the combination. This meeting marks the first drug-related adcomm in nine months.

• The FDA expressed significant concerns regarding AstraZeneca's oral SERD, camizestrant, for HR-positive, HER2-negative breast cancer. Despite the Phase 3 SERENA-6 study showing a 56% decrease in the risk of death or disease progression (median PFS of 16 months vs. 9.2 months in controls), the agency questioned the clinical meaningfulness of this improvement and the novel trial design involving switching treatment based on ESR1m detection prior to radiographic progression, a paradigm without prior FDA approval.
• AstraZeneca's AKT inhibitor, Truqap, in combination with abiraterone for metastatic hormone-sensitive prostate cancer, also faces FDA skepticism. While the Phase 3 CAPItello-281 trial met its primary endpoint with a 19% improvement in radiographic PFS, the FDA noted the overall benefit appeared small. A key concern was the lack of clear delineation of treatment benefit attributable solely to Truqap, given its combination with an already effective backbone therapy, suggesting a statistically significant OS improvement might be needed.
• The upcoming April 30 advisory committee meeting is notable as the first drug-related adcomm in nine months, a significant departure from their historical regular use. Experts like Steven Grossman of HPS Group highlighted the importance of these meetings for FDA's transparency and functioning, suggesting their recent absence points to an 'emphasis on fiat decision-making.' The FDA's briefing documents for both drugs underscore fundamental issues in trial design that limit the validity of results and the assessment of clinical benefit.

FDA Questions Camizestrant's ESR1m-Driven Switch Strategy

ESR1 mutation testing in circulating tumor DNA (ctDNA) represents the primary biomarker strategy studied across camizestrant trials, with the most comprehensive evaluation occurring in the SERENA-6 trial. This study tested 3,256 patients with ER-positive, HER2-negative advanced breast cancer for ESR1 mutations in ctDNA every 2-3 months, ultimately identifying 315 eligible patients with detected mutations who had received at least 6 months of first-line aromatase inhibitor plus CDK4/6 inhibitor therapy. The innovative approach involved switching therapy upon ctDNA-detected emergence of ESR1 mutations—termed "molecular progression"—ahead of traditional anatomic or clinical progression, demonstrating the clinical utility of liquid biopsy for identifying molecular cancer evolution.

Complementary biomarker research has revealed significant insights into ESR1 mutation patterns and co-occurring alterations. Analysis of FFPE tissue biopsy samples from metastatic sites identified ESR1 mutations in 63.2% of patients, with p.D538G and p.Y537S representing the most frequent alterations at 45.5% and 27.2% respectively. Co-mutations in actionable pathways, particularly PIK3CA, were observed in 41.6% of ESR1 mutant tumors, while recurrent ESR1-CCDC170 gene fusions were also identified. These findings highlighted the potential utility of tissue-based mutation detection as a viable alternative to liquid biopsy, particularly in resource-limited settings.

Patient selection strategies across camizestrant trials have consistently targeted women with ER-positive, HER2-negative metastatic breast cancer who were refractory or intolerant to prior therapy, with specific inclusion of patients with visceral disease and liver metastases. Efficacy has been demonstrated regardless of baseline ESR1 mutation status in heavily pre-treated populations, including those with prior CDK4/6 inhibitor exposure. The SERENA-1 combination studies with capivasertib specifically enrolled patients with PIK3CA/AKT1/PTEN alterations, while SERENA-2 stratified randomization by previous CDK4/6 inhibitor treatment and presence of liver and/or lung metastases, establishing broad applicability across diverse patient subgroups within the ER-positive, HER2-negative advanced breast cancer population.

Current Treatment Paradigms in HR+/HER2- Breast Cancer

Current standard of care treatments for breast cancer are defined according to established guidelines including the 2022 Japanese Breast Cancer Clinical Practice Guidelines and NCCN recommendations, with treatment strategies tailored to molecular subtype, stage, and patient characteristics. Standard approaches include surgery, radiation, endocrine therapy, and chemotherapy, which have proven effective in reducing recurrence and improving survival outcomes.

• Endocrine therapy serves as the cornerstone treatment for HR+/HER2- breast cancer, which constitutes approximately 70% of all breast cancer cases, with CDK4/6 inhibitors (ribociclib, palbociclib, and abemaciclib) providing treatment intensification for higher-risk patients by targeting cell cycle progression from G1 to S phase

• Oncotype DX Recurrence Score (ODX-RS) guides adjuvant treatment decisions in ER-positive/HER2-negative early breast cancer, with ODX-RS ≤25 showing significantly better overall survival than ODX-RS ≥26, and age-specific thresholds providing additional prognostic value for treatment planning

• Dual HER2 blockade with trastuzumab plus pertuzumab has become standard neoadjuvant therapy for HER2-positive breast cancer according to CSCO and NCCN guidelines, demonstrating superior efficacy compared to trastuzumab monotherapy with pooled odds ratio of 1.81 for improved pathological complete response rates

• Antibody-drug conjugates have established therapeutic efficacy in HER2-low breast cancer patients (IHC 1+ or 2+ with negative in situ hybridization), with companion diagnostics using 4B5 required to determine indications for trastuzumab-deruxtecan, particularly for HER2-ultralow evaluations

• Genomic testing and multigene assays are recommended to guide chemotherapy decisions and individualize treatment planning, with standard clinicopathologic factors remaining essential regardless of mode of presentation (screen-detected versus symptomatic)

• De-escalated adjuvant therapy represents an appropriate option for selected elderly patients (≥70 years) with favorable disease profiles, while adjuvant bisphosphonates are recommended in postmenopausal women to reduce recurrence and improve survival

Ensuring Long-Term Benefit in Early Intervention for Breast Cancer

Recent long-term follow-up data demonstrates substantial improvements in breast cancer outcomes over the past three decades, with contemporary studies showing encouraging durability of response across multiple treatment modalities. Japanese registry data analyzing 10-year mortality patterns in elderly patients diagnosed between 2008-2012 reveals distinct prognostic profiles by molecular subtype, with HER2-positive and triple-negative breast cancers showing increased breast cancer-related deaths with advancing age, particularly in stages II and III disease. Meanwhile, Indian early detection program data spanning 2008-2018 demonstrates robust long-term outcomes with 10-year overall survival of 79.0% and disease-free survival of 76.2%, representing significant improvements over historical cohorts.

Molecular subtype continues to be a critical determinant of long-term durability, with evolving treatment paradigms showing differential impact across breast cancer subtypes. Recent validation studies of MammaPrint in invasive lobular carcinomas demonstrate up to 11-fold higher risk of distant metastasis in high-risk groups, while comprehensive molecular profiling data from 2024 shows patients with ER-high-positive (≥2/3) HER2-negative disease achieving significantly superior disease-free and overall survival compared to ER-intermediate or ER-negative cohorts. Triple-negative breast cancer maintains the most challenging long-term prognosis, with recent data showing 5- and 10-year progression-free survival of 84% compared to 95% and 81% for luminal A disease, and median overall survival of only 9-15.6 months following liver metastasis development.

Treatment advances have fundamentally transformed long-term outcomes, with comprehensive cancer center data spanning 1990-2007 demonstrating progressive improvements in 5-year disease-specific survival from 89% to 96%. Contemporary targeted therapies show particular promise for sustained responses, with final MONALESSA-2 results demonstrating significant overall survival benefit for ribociclib plus endocrine therapy in HR-positive disease, while trastuzumab deruxtecan shows superior progression-free survival compared to trastuzumab emtansine in HER2-positive advanced disease. Notably, hormone receptor-positive cancers exhibit unique recurrence kinetics with over half of recurrences occurring beyond 5 years, leading to evolving extended endocrine therapy strategies that challenge traditional 5-year treatment paradigms and emphasize the importance of sustained surveillance and intervention strategies.

AstraZeneca's Oncology Pipeline Under the Regulatory Microscope

The upcoming FDA advisory committee meeting for two of AstraZeneca's oncology candidates, camizestrant and Truqap, represents a pivotal moment for the company and the broader pharmaceutical industry. This rare convening of an adcomm for late-stage assets underscores significant regulatory questions that could reshape treatment paradigms and development strategies.

For camizestrant, an oral selective estrogen receptor degrader (SERD) targeting HR-positive, HER2-negative breast cancer, the FDA's skepticism centers on the clinical meaningfulness of its efficacy data and the novelty of its trial design. While SERDs are a crucial class, particularly for patients with ESR1 mutations, and oral formulations offer convenience over injectables like fulvestrant, these concerns could delay or even derail its path to market. This would be a setback for AstraZeneca in a competitive landscape where other oral SERDs are already approved or in advanced development. The outcome will provide critical insights into the FDA's evolving expectations for innovative trial designs and the threshold for demonstrating clinically meaningful benefit.

Truqap (capivasertib), an AKT inhibitor, faces a different challenge. Already approved for a subset of HR-positive, HER2-negative breast cancer patients with specific PIK3CA/AKT1/PTEN alterations, its proposed expansion into metastatic hormone-sensitive prostate cancer in combination with abiraterone is under scrutiny. Despite a reported 19% improvement in radiographic progression-free survival, the FDA has questioned the overall magnitude of benefit and, crucially, the clear attribution of this benefit to capivasertib within the combination. This highlights a growing regulatory focus on the incremental value of adding new agents to existing standards of care, especially when the individual contribution of each component is not distinctly evident.

Beyond the immediate impact on AstraZeneca's portfolio, these discussions could set new precedents for regulatory expectations across oncology. Companies developing combination therapies or employing novel trial methodologies may face increased pressure to provide robust evidence of both clinical significance and the distinct contribution of each drug. The industry will be watching closely to understand the FDA's stance on these critical issues.